what if nicknamed WHAT-IF? for the question, “will having alcohol treatment improve functioning?”

The Pharmacotherapy for hazardous drinking in HIV-infected women: a randomized trial, aims to enroll 240 women with HIV infection who exceed recommended drinking levels (>7 drinks per week). The study will determine whether a specific drug, naltrexone, will help reduce drinking levels in HIV-infected women, thus improving their HIV-related outcomes such as adherence to medication, CD4 count and viral load. Women are randomized to take naltrexone (50mg) or placebo every day for 4 months. Outcomes, assessed at 2-months, 4-months, and 7-months, include alcohol consumption, HIV medication adherence, HIV disease control and progression, and risky sexual behavior. Enrollment began in December of 2012, and has now concluded. The data is still available for anyone interested in submitting a concept.